2008•Zhongguo jiceng yiyaoRequires access

Cost-effectiveness analysis of zhibituo and simvastatin in treatment of hyperlipemia

Jinping Zhang

Open publisher page 0 citations

Abstract

Objective To explore the cost-effectiveness analysis of zhibituo and simvastatin in treatment of hyperlipemia. Methods 68 cases with hyperlipemia were divided into two groups randomly:group A were treated with imvastatin (n = 33),group B were treated with zhibituo(n = 35). The data was evaluated with eost-effectiveneas analysis. Results The cost of the two groups was 462.56 yuan and 257.60 yuan respectivdy. The effective rate was 74.28 % and 73.9.3 %respectivdy. The cost-effectiveness ratio was 6.23 and 3.48 respectively. The increased cost-effectiveness ratio of group A vs group B was 585.6. No significant differences were found in both effective rate and ADRS between two groups(P>0.05).Conclusion Zhibituo was an effective and safe drug in treating hyperlipidemia as well as simvastatin. But zhibituo was better than simvastatin based on the oost-effeetiveness analysis. Key words: Hyperlipemias;  Zhibituo;  Simvastation;  Ecomomics, pharmaceutical

About this research paper

What this paper is about

Objective To explore the cost-effectiveness analysis of zhibituo and simvastatin in treatment of hyperlipemia. Methods 68 cases with hyperlipemia were divided into two groups randomly:group A were treated with imvastatin (n = 33),group B were treated with zhibituo(n = 35). The data was evaluated with eost-effectiveneas analysis. Results The cost of the two groups was 462.56 yuan and 257.60 yuan respectivdy. The effective rate was 74.28 % and 73.9.3 %respectivdy. The cost-effectiveness ratio was 6.23 and 3.48 respectively. The increased cost-effectiveness ratio of group A vs group B was 585.6. No significant differences were found in both effective rate and ADRS between two groups(P>0.05).Conclusion Zhibituo was an effective and safe drug in treating hyperlipidemia as well as simvastatin. But zhibituo was better than simvastatin based on the oost-effeetiveness analysis. Key words: Hyperlipemias;  Zhibituo;  Simvastation;  Ecomomics, pharmaceutical

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To explore the cost-effectiveness analysis of zhibituo and simvastatin in treatment of hyperlipemia. Methods 68 cases with hyperlipemia were divided into two groups randomly:group A were treated with imvastatin (n = 33),group B were treated with zhibituo(n = 35). The data was evaluated with eost-effectiveneas analysis. Results The cost of the two groups was 462.56 yuan and 257.60 yuan respectivdy. The effective rate was 74.28 % and 73.9.3 %respectivdy. The cost-effectiveness ratio was 6.23 and 3.48 respectively. The increased cost-effectiveness ratio of group A vs group B was 585.6. No significant differences were found in both effective rate and ADRS between two groups(P>0.05).Conclusion Zhibituo was an effective and safe drug in treating hyperlipidemia as well as simvastatin. But zhibituo was better than simvastatin based on the oost-effeetiveness analysis. Key words: Hyperlipemias;  Zhibituo;  Simvastation;  Ecomomics, pharmaceutical

Key concepts: Simvastatin, Medicine, Hyperlipidemia, Internal medicine, Significant difference, Group B, Gastroenterology, Endocrinology

Related papers

Back to paper searchBrowse research topicsOriginal source
Cost-effectiveness analysis of zhibituo and simvastatin in treatment of hyperlipemia — Research Paper | ScholarLens